Trial of Oxford’s promising COVID vaccine resumes after brief pause

The university insisted that it was “committed to the safety of our participants and the highest standards of conduct in our studies and will continue to monitor safety closely.”Pauses in drug trials are commonplace but the temporary hold led to a sharp fall in AstraZeneca’s share price following the announcement Tuesday. Italy’s health minister, Roberto Speranza, welcomed the resumption of the vaccine trial, but warned that prudence was still necessary.”Science is at work to give the world efficient and secure treatments and vaccines,” he said. Specifically, the woman is said to have developed symptoms consistent with transverse myelitis, a rare inflammation of the spinal cord. 07:38

Dr. Get Breaking News Delivered to Your Inbox

The vaccine being developed by Oxford and AstraZeneca is widely perceived to be one of, if not the strongest contender among the dozens of coronavirus vaccines in various stages of testing around the world.British Health Secretary Matt Hancock welcomed the restart, saying in a tweet that it was “good news for everyone” that the trial is “back up and running.”The university said in large trials such as this “it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety.”

Dr. During the third and final stage of testing, researchers look for any signs of possible side effects that may have gone undetected in earlier patient research. Anthony Fauci, the top infectious disease expert on the U.S. government’s coronavirus task force, agreed on Wednesday that the temporary halting of the Phase-3 Oxford vaccine trial was “not uncommon.” Being alert to potential adverse reactions with any new vaccine is part of the process, he explained. 

Coronavirus: The Race To Respond

House Dems launch probe into political interference in CDC reports

Dr. The move came less than a week after the study was suspended following a reported possible side-effect in a U.K. Volunteers from some of the worst affected countries — Britain, Brazil, South Africa and the U.S. and the other by Pfizer and Germany’s BioNTech. 
First published on September 14, 2020 / 5:43 AM — are taking part in the trial. Charlotte Summers, a lecturer in intensive care medicine at the University of Cambridge, said the pause was a sign that the Oxford team was putting safety issues first, but that it led to “much unhelpful speculation.””To tackle the global COVID-19 pandemic, we need to develop vaccines and therapies that people feel comfortable using, therefore it is vital to maintaining public trust that we stick to the evidence and do not draw conclusions before information is available,” she said.Scientists and others around the world, including experts at the World Health Organization, have sought to keep a lid on expectations of an imminent breakthrough for coronavirus vaccines, stressing that vaccine trials are rarely straightforward. In a statement, the university confirmed the restart across all of its U.K. AstraZeneca starts phase 3 vaccine trials


Brazil’s health regulator Anvisa on Saturday said it had approved the resumption of tests of the “Oxford vaccine” in the South American country after receiving official information from AstraZeneca. clinical trial sites after regulators gave the go-ahead following the pause on Sunday.”The independent review process has concluded and following the recommendations of both the independent safety review committee and the U.K. “In the meantime, the key continues to be our behavior.” Italy, which was ground zero for Europe’s outbreak, is one of the main countries investing in the AstraZeneca vaccine, but the U.K. Because of their large size, the studies are considered the most important study phase for picking up less common side effects and establishing safety. The Oxford-AstraZeneca study had previously been stopped in July for several days after a participant developed neurological symptoms that turned out to be an undiagnosed case of multiple sclerosis that researchers said was unrelated to the vaccine. Hopefully they’ll work it out and be able to proceed along with the remainder of the trial.”Oxford said that globally some 18,000 people have received its vaccine so far. Fauci on the race for a COVID-19 vaccine


Dr. Gottlieb says vaccine unlikely to be widely a… Although Oxford would not disclose information about the patient’s illness due to participant confidentiality, an AstraZeneca spokesman said earlier this week that a woman had developed neurological symptoms that prompted the pause. The trials also assess effectiveness by tracking who gets sick and who doesn’t between patients getting the vaccine and those receiving a dummy shot. and the U.S. Ashish Jha: “We have not rounded a corner” on virus vaccine

Cost of inequality: Workers lose thousands a year, study says

Rare dolphins return to Hong Kong waters

Trump’s campaign strategy “is to create panic,” Jeh Johnson says


“It’s really one of the safety valves that you have on clinical trials such as this,” he told “CBS This Morning.” “So it’s unfortunate that it happened. — which has stumped up about $1.2 billion for the development of the drug — are also heavily invested.Two other vaccines are in huge, final-stage tests in the United States, one made by Moderna Inc. patient. regulator, the MHRA, the trials will recommence in the U.K.,” it said. Oxford’s COVID vaccine trial “back up and running” after brief pause for safety check

September 14, 2020 / 10:27 AM

London — Oxford University announced over the weekend that it was resuming a trial for a coronavirus vaccine it is developing with pharmaceutical company AstraZeneca.